Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CDC25C | P30307 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12229080 | 0.85 | CYP19A1 (0.56) | CYP19A1NPC1RAB9ASIGMAR1HRH4 | |
| SCHEMBL18925230 | 0.83 | NOTUM (0.55) | ESRRGCYP19A1NPC1RAB9AMEN1 | |
| SCHEMBL10094368 | 0.81 | GUSB (0.52) | KDREPHB4TEKCYP11B1 | |
| SCHEMBL12194478 | 0.81 | MEN1 (0.56) | CYP19A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL10094367 | 0.80 | HSP90AA1 (0.57) | ESRRGNPC1RAB9AMEN1KMT2A | |
| SCHEMBL10094376 | 0.80 | HSP90AB1 (0.57) | ESRRGCYP19A1NPC1RAB9AMEN1 | |
| SCHEMBL23386948 | 0.78 | CYP19A1 (0.60) | CYP19A1 | |
| SCHEMBL10094377 | 0.75 | HSP90AB1 (0.62) | CYP19A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL10094375 | 0.75 | HPGD (0.54) | NPC1RAB9AMEN1KMT2AKDR | |
| SCHEMBL10094370 | 0.75 | SIGMAR1 (0.50) | ESRRGMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| WO-2021087096-A1 | P53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | ESRRG 2144/4885CYP19A1 1690/4885NPC1 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.